Skip to content

Feasibility of dual channel low field TMS for improvement of brain functioning.

Feasibility of dual channel low field TMS as a plasticity modulator: Pilot in healthy volunteers.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON21943
Enrollment
70
Registered
2012-02-20
Start date
2012-03-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired connectvity

Interventions

Two electromagnets are fitted over the EEG/NIRS cap. Magnetic field flux densities <5mT are applied to the head. The microTMS stimulus will consist of pulsed magnetic stimulation. Pulses will consist

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult healthy volunteers; 2. Native Dutch speaker; 3. Age 18-80.

Exclusion criteria

Exclusion criteria: 1. Psychiatric or neurological disease, present or past; 2. Visual or hearing limitations that can not be corrected for; 3. Alcohol or drug addiction; 4. Excessive intake of coffee (>10 units per day) or alcohol (>10 units per day); 5. Recent use of alcohol (within 1 day); 6. Recent use (within four weeks) of cannabis or any other non-prescription psychopharmaca; 7. Presence in the body of MRI-incompatible implants, electronic implants (e.g. cardiac pacemakers), or connectors of electronic equipment (e.g. electrodes); 8. Pregnancy, lactation.

Design outcomes

Primary

MeasureTime frame
1. The change in effective brain connectivity estimated by DCM for EEG; 2. The differences in concentrations of oxygenated (HBo) and de-oxygenated blood before, during and after the treatment (as estimated from NIRS measurements).

Secondary

MeasureTime frame
1. The estimated coherence of EEG recordings between electrodes; 2. The ERP from EEg recordings; 3. The accuracy from the cognitive test; 4. The accuracy from the Digit symbol substitution test; 5. The differences in concentrations of oxygenated (HBo) and de-oxygenated blood before, during and after the treatment (as estimated from NIRS measurements).

Contacts

Public ContactCurcic-Blake Branislava

Antonius Deusinglaan 2

b.curcic@umcg.nl+31 (0)50 5267584

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)